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TREATMENT PATTERNS AND OUTCOMES AMONG OLDER EXENATIDE BID
USERS COMPARED TO INSULIN GLARGINE USERS
Gaebler JA1, Schultz JF2, Blickensderfer A3, Wenten M1, Riedel A4, Harley C5
1Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 2University of Minnesota, Duluth, MN, USA,
3Amylin Pharmaceuticals, Inc., Chesterfield, MO, USA, 4i3 Innovus, Eden Prairie, MN, USA, 5i3
Innovus, Palo Alto, CA, USA
OBJECTIVES:We evaluated treatment patterns, hypoglycemic events, glycemic con-
trol and medical costs for patients 60y with type 2 diabetes mellitus (T2DM) newly
initiating treatment on exenatide BID (ExBID) or insulin glargine (IG).METHODS:Med-
ical, pharmacy and lab data for commercial and Medicare Advantage enrollees were
obtained fromadministrative claims froma large, national health plan. Subjectswere
identified fromMay2005 toDec2008with6-mobaselineand12-mo follow-upperiods.
Subjects with any insulin treatment during baseline were excluded. Propensity score
(PS) matching (1:1) of ExBID and IG subjects was used to create balanced cohorts.
Logistic regression models were used to analyze medication adherence (Medication
Possession Ratio (MPR) 80%), therapy persistence (gap of 60 days in treatment 
discontinuation), any acute hypoglycemic event, and glycemic control (follow-upA1C
levels of7%). RESULTS: The finalmatched study sample included 3,263 subjects per
cohort; average age was 65y (SD 4.9); 48% were female; 83% were enrolled in a com-
mercial health plan. In the follow-up period, ExBID patients experienced significantly
fewer hypoglycemic events compared to IG patients (15 vs. 40, p0.001). Subjects in
theExBIDcohortwerealsomore likely toobtainanMPR80% (OddsRatio (OR)1.93,
CL1.72-2.17), less likely todiscontinue therapy (OR0.28,CL0.25-0.31) and less likely to
have any acute hypoglycemic event (OR0.48, CL 0.26-0.88) during the follow-up pe-
riod. For those with valid A1C levels in both baseline and follow-up periods (N669;
ExBID359, IG310), ExBID subjects were more likely to achieve A1C 7% (OR1.62,
CL 1.11-2.35) compared to IG subjects. Associated medical costs were similar for both
groups. Results were comparable for patients  65y. CONCLUSIONS: Older ExBID
subjects were more likely to adhere to therapy and achieve A1C 7% and less likely
to discontinue therapy or experience any acute hypoglycemic event than older IG
subjects.
PDB2
EVALUATING ONE-YEAR STABILITY OF THE TOTAL ILLNESS BURDEN INDEX
Billimek J1, Cantrell R2, Greenfield S1, Kaplan S1
1University of California Irvine, Irvine, CA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: The Total Illness Burden Index (TIBI) is a well-validated, patient-
reported measure of the presence and severity of medical conditions comorbid to
an index condition and is an important component of the Potential for Benefit
Conceptual Model, shown to predict response to treatment in diabetes. The objec-
tive of this research was to determine the one-year stability of the TIBI.METHODS:
We identified patients with type 2 diabetes enrolled in the Reducing Racial Dispar-
ities in Diabetes Coached Care (R2D2C2) studywho had completed the 47-item TIBI
at baseline and one year follow-up, and whose antihyperglycemic medication reg-
imen had not changed (n364). For this sample, we estimated standard error of
measurement (SEM) for the TIBI and compared changes in TIBI scores using paired
t-tests and limits of agreement. RESULTS: SEM for the TIBI-47 was 0.90. Scores for
baseline and follow-up were 3.52 and 2.88 respectively (range  0-13), mean im-
provement  0.64, within the SEM. 82.2% of respondents had a change in the TIBI
score of 3 points. Minor improvements ( 5% of scale range) were observed in
transient symptoms (e.g. fluwith cough, shortness of breath, etc.) versus diagnoses
(e.g. congestive heart failure, stroke, etc.). All changes in symptoms were within
SEM for respective TIBI subdimensions. CONCLUSIONS: TIBI scores appeared to be
highly stable for this study sample over the one-year observation period. Small
changes observed in symptom severity itemsmay be due to effective clinical man-
agement. Further research is needed to distinguish observed differences due to
treatment response from measurement error.
PDB3
LONG-TERM ANTIPROTEINURIC EFFECT OF ALISKIREN IN DIABETIC PATIENTS
WITH PERSISTENT ALBUMINURIA DESPITE CHRONIC ACEI OR ARB TREATMENT
Huang W1, Mersy JH1, Levin P2
1Greater Baltimore Medical Center, Baltimore, MD, USA, 2Bay West Endocrinology Associates,
Baltimore, MD, USA
OBJECTIVES: Studies showed dual blockade of renin-angiotensin-aldosterone sys-
tem with ACEI and ARB had produced little gain with significant side effects in
proteinuric patients. Here we evaluated the real-world effectiveness of long-term
antiproteinuric effects of a novel dual blockade with the direct renin inhibitor
aliskiren addition on chronic ACEI or ARB treatment in diabetic patients with per-
sistent albuminuria. METHODS: We retrospectively collected data from the elec-
tronic database of Baywest Endocrinology Associates. Aliskiren150- 300mg daily
was added on chronic ACEI/ARB treatment (mean known duration 6 years). The
Cockroft-Gault formula was used to estimate the glomerular filtration rate (eGFR).
TheWilcoxon Signed Ranks test andKendall’s tau-b correlation analysiswere used
to calculate statistical significance. p0.05 was considered significant. RESULTS:
Twenty-four (mean age 64 years) patients were selected, with a mean observation
time 15 months before and 20 months after aliskiren addition. There was a signif-
icant rise in urinary albumin-to-creatinine ratio (Ualb/Cr) [unit: mg/g, 146.3 (16.1-
1978.7) vs. 51.0 (34-1170.3)] and SBP (unit: mmHg, 158  19 vs. 142 21) in these
patients at baseline (i.e., whenAliskirenwas added)when comparedwith that of 15
months before (p0.05). And therewas a significant decline in albuminuria and SBP
20 months after aliskiren addition: reduced median Ualb/Cr was 73.3%, reduced
mean SBP was 24 mmHg (p0.001). However, reduction in Ualb/Cr was not related
to reduction in SBP (p0.05). No changes were found in the DBP, HbA1c, serum
creatinine and eGFR. A small increment of serum potassium levels was detected
after aliskiren addition( unit: mmol/L, 4.50.6 vs 4.4  0.4 mmol/L at baseline,
p0.05 ). During the study, no adverse events, including symptoms of hyperkale-
mia and hypotension, were documented. CONCLUSIONS: Aliskiren addition to
ACEI/ARB may have extra antiproteinuric effects that might be independent on BP
reduction and held without rebound as long as 1.5 year follow-up.
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MODELING HEALTH AND ECONOMIC OUTCOMES ASSOCIATED WITH
EXENATIDE ONCE-WEEKLY VERSUS INSULIN AND PIOGLITAZONE TREATMENT
FOR TYPE-2 DIABETES
Gaebler JA1, Soto-Campos G2, Alperin PE3, Hoogwerf BJ4, Wintle M1, Maggs D1, Han J1,
Blickensderfer A5, Pencek R1, Bruhn D6, Peskin BR2
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OBJECTIVES: Exenatide once-weekly (ExQW) is a GLP-1 receptor agonist that im-
proves glycemia in patients with type 2 diabetes (T2DM) while eliciting potential
weight loss and improvement in cardiovascular risk factors (blood pressure (BP) and
plasma lipids). In published trials, ExQW resulted in superior reduction in A1C com-
pared tomaximumdaily doses of sitagliptin andpioglitazone (Pio) onmetformin (Met)
background, and to titrated insulin glargine. METHODS: We used the Archimedes
Model, a validated, clinically detailed model of physiology, disease, and healthcare
delivery, to explore potential long-termExQWbenefits and costs.We simulated 20y of
treatment in a virtual population (n19,885) based on individuals with T2DM drawn
from NHANES who were on Met/sulfonylureas (mean age 59y, BMI 33kg/m2, wt
93kg, duration T2DM 9y, baseline A1C 8%). The effects of three treatment regimens
were modeled at simulation start: 1) advancement to insulin at A1C 8% (treat to
target A1C7%), 2) addition of Pio, and 3) addition of ExQW. ExQW’s effect on A1C,
weight, BP, and lipidswas derived from four phase 3 ExQW trials. Medical costs (inpa-
tient, outpatient, ambulatory, treatments) were derived from the Medicare Current
Beneficiary Survey, Medicare Part D data, drugstore.com, and published literature.
Since ExQW is investigational, antidiabetic therapy costswere excluded.RESULTS:At
20y, final mean A1C was 7% in all arms. Compared to insulin and Pio, respectively,
ExQWwas associatedwith relative reductions in finalmeanweight (5% vs. both com-
parators), incidence of first Major Adverse Cardiovascular Event (8.2% and 3.3%), and
CHF (5.1% and 15.0%). All arms showed comparable benefit in controlling neuropathy,
but ExQW showed significantly greater reductions in renal complications. As early as
5y, ExQW demonstrated total cost-savings of $545 and $379 per life-year vs. insulin
and Pio, respectively. CONCLUSIONS: These simulations suggest that the benefits of
ExQWmay translate into clinically and economically meaningful reductions in long-
term outcomes.
PDB5
THE IMPACT OF ANTIDIABETIC-INDUCED HYPOGLYCEMIA ON CLINICAL
OUTCOMES AND RESOURCE UTILIZATION AMONG VETERANS WITH TYPE-2
DIABETES MELLITUS (T2DM)
Zhao Y, Shi L, Fonseca V, Campbell C
Tulane University, New Orleans, LA, USA
OBJECTIVES: To examine the impact of antidiabetic-induced hypoglycemia on
clinical outcomes and resource utilization among T2DM patients in the Veterans
Affairs.METHODS:This retrospective cohort study used electronicmedical records
between 01/01/2004 and 09/01/2010 from the Veterans Integrated Service Network
(VISN) 16 datawarehouse. Patientswere required to have at least 2 records of T2DM
ICD-9-CM diagnosis (250.xx except for 250.x1 and 250.x3). The first dispense date of
a new antidibetic agent (index drug) were defined as the index date. No hypoglycemia
diagnosis was allowed during the one-year pre-index period. The hypoglycemia co-
hort and control cohort were defined by ICD-9-CM diagnosis of hypoglycemia (250.8,
251.0, 251.1 and251.2)within the index-treatmentperiod andnohypoglycemiaduring
the one-year post-index period, respectively. Clinical outcomes included hemoglobin
A1c, cardiovascular diseases (CVD) andmicro-vascular complications. Resource utili-
zation included hospitalizations and emergency room (ER) visits. Clinical outcomes
were compared by Cox regression models, controlling for age, race, index drug, renal
functions, andbaseline variables: A1c, Charlson comorbidity index (CCI), and resource
utilization. RESULTS: Among 42,437 T2DM patients, 369 patients of the hypoglyce-
mia cohort and 42,068 patients of the control cohort differed in racial and marital
status, baseline CCI and resource utilization. The hypoglycemia cohort was more
likely to receive insulin/sulfonylurea as index drug. The post-index A1c was nu-
merically higher in the hypoglycemia cohort than control cohort (10.12 vs 9.87, p
0.0602). The hypoglycemia cohortwasmore likely to develop CVD (HR1.32, 95%CI:
1.13-1.54) and 40%more likely to developmicro-vascular complications, compared
with the control cohort. Risks of hospitalization and ER visit were higher for the
hypoglycemia cohort than control cohort (18.2% vs. 9.2%, 32.3% vs. 20.7%, both
p-values  .0001, respectively). CONCLUSIONS: Patients with hypoglycemia may
lead toworse clinical outcomes andhigher risks of hospitalization and ER visit than
those without.
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LONG-TERM EFFECTIVENESS OF MANAGING DIABETES WITH THE CHRONIC
CARE MODEL: SIMULATIONS PERFORMED USING ARCHES
Zgibor JC1, Kuo S1, Schuetz CA2, Roberts MS1, Cohen MD2
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A91V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
OBJECTIVES: The Chronic Care Model (CCM) is a framework for enhancing health
care delivery for chronic illnesses through six elements: self-management support,
delivery system design, community resources, organizational support, decision
support, and clinical information systems. The CCM was implemented at USAF
Wilford Hall Medical Center from 2006 through 2008, but little is known about its
long-term effectiveness. METHODS: We used the ARCHeS interface to the Archi-
medes model to forecast the effectiveness of the CCM compared to the current
levels of care in the US (CLC) over 20 years for patients with type 2 diabetes. We
modeled the CCM intervention effects on health outcomes and disease progression
of diabetes based on empirical biomarker change results from three-year military-
based clinical data. The primary analysis focused on the effectiveness in terms of
diabetes related health outcomes, while a secondary analysis considered cost-
effectiveness from a health care system perspective. RESULTS: Compared with
CLC, the relative reductions in 20-year Kaplan-Meier incidence due to the CCM
were 10.3%, 3.8%, 5.8%, 6.0%, 11.1% for myocardial infarction, proliferative diabetic
retinopathy, blindness, foot ulcer, and foot amputation, respectively. The CCM
resulted in a 6.7% relative reduction in coronary heart disease death, and a 0.6%
relative reduction in all-cause death. The CCM had no compelling benefits for
reducing the incidence of stroke or nephropathy. CONCLUSIONS: We found the
CCM lowers the risk of morbidity and mortality from diabetes in a military popu-
lation. Our results using ARCHeS simulations are broadly consistent with previous
Markov model studies but extend those results by providing a more detailed un-
derstanding of the specific health outcomes affected by the CCM, as well as the
impact on comorbidities associated with diabetes.
PDB7
DIET THERAPIES IN PATIENTS WITH TYPE-2 DIABETES: A MIXED-TREATMENT
COMPARISON OF RANDOMIZED CONTROL TRIALS
Harrington AR, Malone D
The University of Arizona, Tucson, AZ, USA
OBJECTIVES: Type 2 Diabetes Mellitus (TTDM) contributes to the body’s inability to
produce a sufficient amount of insulin in order to sustain glucose levels necessary
for energy production. The study aim is to determine the association between
multiple diet therapies and the clinical profile of adult patients with TTDM.
METHODS: We conducted a mixed-treatment comparison meta-analysis of ran-
domized diet therapies for TTDM patients. Therapies included high carbohydrate
and isocaloric (HCI); high carbohydrate and hypocaloric (HCH); low carbohydrate
and isocaloric (LCI); and low carbohydrate and hypocaloric (LCH). A systematic
literature search was conducted through December 2010. The primary outcomes
measured were hemoglobin A1c (HbA1c), high-density lipoprotein (HDL) choles-
terol, low-density lipoprotein (LDL) cholesterol, and triglycerides. These outcomes
were dichotomized based upon American Diabetes Association (ADA) standards. A
diet was considered successful if the patient’s HbA1c was 7%, HDL was 40
mg/dL, LDL was 100 mg/dL, or triglycerides were 150 mg/dL. Mixed-treatment
comparison meta-analysis was used to combine direct, within-trial, and between-
trial comparisons with indirect trial evidence from other trials while maintaining
randomization. Results are reported as odds ratios (OR) and 95% credible intervals
(CI). RESULTS: In total, 10 studies (21 treatment arms and 340 patients) were in-
cluded in the analysis. For bothHbA1c and triglycerides, theHCHdiet yielded lower
measurements compared to the HCI diet (OR: 0.89 CI: 0.04, 20.86; OR: 0.58 CI: 0.02,
15.55, respectively for HbA1c and triglycerides) and LCI diet (OR: 0.47 CI: 0.02, 7.45;
OR: 0.15 CI: 0.001, 6.28, respectively for HbA1c and triglycerides). LDL and HDL
cholesterol measurements were not found to be statistically significantly different
among the four diet types. CONCLUSIONS: This study illustrated no statistically
significant differences existed between the four types of diets with respect to four
clinical outcomes. Further research is necessary to identify an optimal diet combi-
nation for patients with TTDM.
PDB8
EFFECTIVENESS AND ADHERENCE WITH FIXED-DOSE COMBINATION (FDC)
VERSUS COADMINISTERED DUAL THERAPY (CDT) ANTIHYPERGLYCEMIC
REGIMENS: A META-ANALYSIS
Han S, Davies MJ, Lento K, Radican L, Zhang Q
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA
OBJECTIVES: To compare the effect of antihyperglycemic FDCs on A1C and adher-
ence relative to CDTs in clinical practice.METHODS: A 2-part systematic literature
review and meta-analysis were performed to compare the A1C response and ad-
herence between the 2 drug regimens. Inclusion criteria limited articles to studies
that compared equivalent drug components within FDC and CDT. Searches used
Medline, Embase, and Cochrane databases. Of the 1246 identified abstracts, 152
articles were reviewed, and 8met the inclusion criteria. Results were extracted and
pooled in a meta-analysis, using a random-effects model. Unreported standard
deviations were imputed according to the Cochrane Handbook. Cohort compari-
sons were described as mean differences (MD) with 95% confidence intervals (CIs).
RESULTS:A total of 37,173 patients comprised the 16 reported cohort comparisons.
Five comparisons described A1C reductions in FDC and CDT cohorts, and a meta-
analysis revealed a greater reduction in A1C with FDC (MD, 0.5% [95% CI: 0.8,
0.3%]). Eleven comparisons evaluated medication adherence (measured by med-
ication possession ratio [MPR]) between the FDC and CDT cohorts. These 11 cohort
comparisons were divided into 3 subgroups due to different study designs. Five
comparisons described MPR for FDC and CDT cohorts, with higher adherence with
FDC (MD, 12% [95% CI: 5, 19%]). Three comparisons examined patients who
switched from monotherapy to FDC or CDT, with higher adherence for patients
who switched to FDC (MD 8% [95%CI: 6, 10%]). Three comparisons described results
for patients who switched from CDT to FDC or stayed on CDT, with higher adher-
ence for patients who switched to FDC (MD 5% [95% CI, 3, 7%]). CONCLUSIONS:Use
of antihyperglycemic FDCs was associated with lower A1C levels and higher MPRs
compared to CDT in patients with T2DM in clinical practice.
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IMPACT OF EXENATIDE, PEN INSULIN AND VIAL/SYRINGE INSULIN ON
PATIENT OUTCOMES IN A DIABETES POPULATION IN THE UNITED STATES: A
RETROSPECTIVE DATABASE ANALYSIS OF PERSISTENCE AND FIRST-YEAR
COSTS
Rashid N1, McCombs J1, Foster S2, Miller LA2
1USC School of Pharmacy, Los Angeles, CA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: The Objective of this research is to compare health care costs and
medication persistence for patients initiating treatment using exenatide, pen in-
sulin or vial insulin. METHODS: Commercial health plan data [2004 to 2008] were
used to identify episodes of anti-diabetic drug therapy which were then classified
according to treatment history: first observed treatment; restarting a previous ther-
apy [90-day gap in all treatment]; switching therapy; and augmentation therapy.
All exenatide and insulin episodes were selected for this analysis. Multivariate
statisticalmethods adjusted for demographics, drug use history, priormedical care
use, comorbidmedical conditions, and prescription drug profile. Several sensitivity
analyses were conducted. RESULTS: 213,701 episodes of anti-diabetic drug therapy
were identified of which 7,031 patients initiated using exenatide, 21,011 used vial
insulin [VI] and 422 used pen insulin [PI]. Time to all cause discontinuation [TTAD]
wasmeasured for the index drug and all diabetic-related drugs. Pen insulin [PI] was
discontinued 91 days earlier than exenatide [p0.0001], while vial insulin [VI] was
continued 18 days longer than exenatide [p0.01]. PI patients discontinued all
anti-diabetic drugs 34 days earlier than exenatide patients [p0.05] while ex-
enatide andVI patients exhibited similar TTAD for all drugs. Relative to vial insulin,
exenatide use was estimated to reduce first-year medical costs by $4,629
[p0.0001] which was sufficient to offset higher prescription drug costs for ex-
enatide [$519, p0.0001]. Similar cost results were found comparing exenatide to
pen insulin but were not statistically significant, likely due to the limited sample
size for pen insulin. These results were confirmed using propensity scorematching
estimation andwere robust across episode type.CONCLUSIONS: Patients initiating
drug therapy using exenatide incur lower post-treatment costs than similar pa-
tients who initiated treatment using insulin.
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ASSESSING THE ABILITY OF PATIENT REPORTED MEASURES TO DISCRIMINATE
PROXIES FOR TREATMENT RESPONSE
Cantrell R1, Brenneman S2, Kaplan S3, Shen W1, Brekke L2, Billimek J3, Paczkowski R1,
Haynes V4, Greenfield S3, Buesching D1
1Eli Lilly and Company, Indianapolis, IN, USA, 2i3 Innovus, Eden Prairie, MN, USA, 3University
of California Irvine, Irvine, CA, USA, 4i3 Innovus, Basking Ridge, NJ, USA
OBJECTIVES: The Potential for Benefit conceptual model is a framework to identify
subgroups of patients with differential potential for response to treatment. Within
this context, we developed the ENSEMBLE Minimum Dataset (MDS), a collection of
patient reported measures, to assess patient heterogeneity. The objective of this
research is to provide evidence that ENSEMBLE MDSmeasures can be used to form
subgroups that are clinically and statisticallymeaningful in their ability to discrim-
inate proxies for treatment response. METHODS: A cross-sectional survey was
mailed to 3380 type 2 diabetes patients identified from a large administrative
claims database. ENSEMBLE MDS measures included: Total Illness Burden Index
(TIBI), EQ-5D, Psychological Health Questionnaire (PHQ-4), Perceived Stress Scale
(PSS-4), Perceived Social Support (MOS-SS), MacArthur Scale of Subjective Social
Status (M-SSS), MacArthur Income Question (MIQ), Barrett Simplified Measure of
Social Status (BSMSS), Self-reported Depression (DQ), and Self-Reported Health
(SRH). Proxies for treatment response were patient global impression of disease
severity (PGIS), patient global impression of improvement (PGII) and overall disease
burden. We assessed the ability of ENSEMBLE MDS measures to discriminate
among levels of PGIS, PGII, and burden via unadjusted, adjusted, and trend
analyses. RESULTS: A total of 724 patients responded with complete survey data
and were categorized into 3 levels on PGIS, PGII, and burden. TIBI, EQ-5D, PHQ-4,
PSS-4, MOS-SS, andM-SSS discriminated across the levels of PGIS, PGII, and burden
(p  0.05) for all analyses. DQ discriminated burden for all analyses (p  0.01) and
PGII and PGIS for unadjusted and trend analyses (p  0.05). BSMSS only showed
significant trend for burden (p 0.05).CONCLUSIONS: Results of this study provide
evidence that the componentmeasures of the ENSEMBLEMDSdiscriminate among
levels of disease severity, improvement, and burden. Future research includes test-
ing these measures in other disease areas, testing alternative patient reported
measures, and creating a composite scoring algorithm.
PDB11
COMPARISON OF MULTIVARIABLE-ADJUSTED LOGISTIC REGRESSION WITH
PROPENSITY SCORE-MATCHED, PROPENSITY SCORE-STRATIFIED, AND
PROPENSITY SCORE-ADJUSTED LOGISTIC REGRESSION MODELS
Khoza S, Barner JC, Richards K
University of Texas at Austin, Austin, TX, USA
OBJECTIVES: To compare the multivariable-adjusted logistic regression model
with the propensity score-matched, propensity score-stratified, and propensity
score-adjusted logistic regression models in estimating the effect of exposure to
antidepressant agents in increasing the risk of type 2 diabetesmellitus.METHODS:
A retrospective cohort study using the Texas Medicaid prescription claims data-
basewas conducted from January 1, 2002 to December 31, 2009. Patients aged 18-64
years with new prescriptions for antidepressants (exposed group) or benzodiaz-
epines (unexposed group) and without diabetes at cohort entry were included in
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